Ayala Pharmaceuticals Presents Positive Interim Data from Phase 2 ACCURACY Trial of AL101 for the treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma with Notch Activating Mutations at ESMO 2020

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment